{"url":"https://newsforagent.com/news/2026-11-02/eton-pharmaceuticals-baylor-igf1-et-900-license","markdown_url":"https://newsforagent.com/news/2026-11-02/eton-pharmaceuticals-baylor-igf1-et-900-license.md","title":"Eton Pharmaceuticals Licenses Baylor IGF-1 Rights for ET-900","headline":"Eton Pharmaceuticals Licenses Baylor IGF-1 Patent Rights and Submits IND for ET-900 Spasms Program","description":"Eton Pharmaceuticals licensed Baylor College of Medicine IGF-1 patent rights and submitted an IND for a Phase 2 study of mecasermin in up to 20 children.","section":"Partnerships","published_at":"2026-11-02T12:05:17+00:00","modified_at":"2026-11-02T12:05:17+00:00","author":"News Desk","key_takeaways":["Eton Pharmaceuticals licensed patent rights from Baylor College of Medicine covering IGF-1 for infantile and epileptic spasms.","An IND has been submitted for an investigator-sponsored Phase 2 study of mecasermin sponsored by the University of Chicago, with first patient dosing planned in Q1 2027.","The study is expected to enroll up to 20 patients ages 2 to 18 across the University of Chicago, Baylor College of Medicine and UCLA."],"companies":[{"name":"Eton Pharmaceuticals","is_primary":true,"profile_url":"https://akta.pro/company-profiles/00045ul/eton-pharmaceuticals","website":"https://www.etonpharma.com"},{"name":"NIH Funding","is_primary":false,"profile_url":"https://akta.pro/company-profiles/004io88/nih-funding","website":"https://grants.nih.gov"}],"source":{"publisher":"Stock Titan","title":"Eton licenses IGF-1 rights for ET-900 program","url":"https://www.stocktitan.net/news/ETON/eton-pharmaceuticals-announces-licensing-and-initiation-of-et-900-gfko3jt1tp58.html"},"other_sources":[],"tags":["Partnerships","Eton Pharmaceuticals","NIH Funding"],"body_markdown":"Eton Pharmaceuticals licensed patent rights from Baylor College of Medicine covering the use of insulin-like growth factor 1 (IGF-1) for infantile and epileptic spasms and submitted an Investigational New Drug application for a Phase 2 study of mecasermin, the company said in a [Stock Titan](https://www.stocktitan.net/news/ETON/eton-pharmaceuticals-announces-licensing-and-initiation-of-et-900-gfko3jt1tp58.html) report on November 2, 2026. The program is called ET-900.\n\n## How Eton's ET-900 Program Works\n\n[Eton Pharmaceuticals](https://akta.pro/company-profiles/00045ul/eton-pharmaceuticals) is evaluating mecasermin injection, a recombinant form of IGF-1 and the active ingredient in its INCRELEX product, which Eton markets in the United States. The company retains commercial rights to ET-900, which it said would align with its planned entry into pediatric neurology.\n\nThe investigator-sponsored Phase 2 study will be sponsored by the University of Chicago and is expected to enroll up to 20 patients ages 2 to 18 across three sites: the University of Chicago, Baylor College of Medicine and UCLA. Patients will have spasms that have not responded to, or who have been unable to tolerate, hormonal therapy and vigabatrin. They will receive twice-daily subcutaneous injections during an initial three- to five-week treatment period, with an additional course available to certain patients based on clinical response. The study will assess spasm resolution, changes in daily spasm frequency, and resolution or improvement of associated EEG abnormalities, along with safety, tolerability and adaptive functioning. Initial enrollment and dosing are targeted for the first quarter of 2027.\n\nResearch led by Dr. John W. Swann, Ph.D., Distinguished Emeritus Professor of Pediatrics and Neuroscience at Baylor College of Medicine, and funded by CURE Epilepsy identified impaired IGF-1 signaling as a potential contributor to epileptic spasms. In an animal model, treatment with recombinant human IGF-1 reduced daily spasm counts by approximately 50% and eliminated spasms in 20% of treated animals.\n\n\"These spasms can have devastating and lifelong consequences for children and their families, and there remains a significant and urgent need for new therapeutic approaches due to high rates of resistance to current therapies,\" said Sean Brynjelsen, Chief Executive Officer of Eton Pharmaceuticals.\n\n## Eton's Rare Disease Portfolio and Revenue Targets\n\nAccording to akta.pro [company records](https://akta.pro/company-data), Eton reported first-quarter 2026 revenue of $24.3 million, up 73% year-over-year, and raised its full-year 2026 revenue guidance to over $120 million from a previous $110 million estimate. The same records list long-term targets of a $200 million revenue run rate by 2027 and $500 million by 2030.\n\n## Eton's Earlier Licensing and Launch Moves\n\nIn October 2026, Eton and Aquestive Therapeutics announced an exclusive U.S. license for LIBERVANT, a diazepam buccal film for seizure clusters, Stock Titan reported. In September 2026, Eton launched IMPAVIDO (miltefosine) capsules in the U.S. with exclusive commercialization rights, distributed through Anovo Specialty Pharmacy with $0 co-pay for eligible commercially insured patients, according to Stock Titan.\n\n## ET-900's First Patient Dosing Timeline\n\nEton said initial enrollment and dosing for the Phase 2 study are targeted for the first quarter of 2027. Mecasermin is not FDA-approved for the treatment of infantile or epileptic spasms, and its safety and efficacy for these uses have not been established.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}